2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2024

Effect of a Revised Counselor Training on Skills Development and Knowledge of Volunteers with Systemic Lupus Erythematosus
Abstract Number: 268

Effect of Abatacept Treatment on T Cells in Muscle Tissue and Peripheral Blood in Polymyositis and Dermatomyositis Patients
Abstract Number: 1273

Effect of Anti-Cyclic Citrullinated Protein Antibodies and Rheumatoid Factor on Bone Erosions in Early Rheumatoid Arthritis Patients Using HR-pQCT: A Cross-Sectional Study
Abstract Number: 2174

Effect of Anti-Rheumatic Treatment on Selenium Levels in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Abstract Number: 1640

Effect of BMI on Baricitinib Efficacy: Pooled Analysis from Two Phase 3 Rheumatoid Arthritis Clinical Trials
Abstract Number: 394

Effect of BMI on Symptoms and Outcomes in Juvenile Idiopathic Arthritis Patients
Abstract Number: 2379

Effect of Canakinumab Treatment on Health-Related Quality of Life in Patients with Periodic Fever Syndromes
Abstract Number: 372

Effect of Chronicity on Pain Behaviors in Collagenase Induced Non-Inflammatory Monoarthritis in Mice
Abstract Number: 2795

Effect of Complete or Partial Proteinuria Recovery Compared to No Recovery at 2 Years after the Diagnosis of Lupus Nephritis on Long Term Outcomes
Abstract Number: 1687

Effect of Concomitant Conventional Disease-Modifying Antirheumatic Drugs (DMARDs) on the Efficacy and Safety of Ixekizumab in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis
Abstract Number: 2L

Effect of Denosumab Compared with Risedronate in Glucocorticoid-Treated Individuals: Results from the 12-Month Primary Analysis of a Randomized, Double-Blind, Active-Controlled Study
Abstract Number: 2633

Effect of Different Biologic Agents on Lipid Profile in Rheumatoid Arthritis
Abstract Number: 1764

Effect of Disease Remission on Organ Damage and Quality of Life in Chinese Patients with Systemic Lupus Erythematosus
Abstract Number: 1742

Effect of DMARD Therapies on NSAID Intake, Quality of Life, and Physical Functioning in Patients with Ankylosing Spondylitis
Abstract Number: 2371

Effect of Etanercept on Several Soluble Biomarkers in a Randomized Controlled Trial of Patients with Erosive Hand Osteoarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].